Dr. Diamond is a lymphoma specialist, a malignant hematologist, and an assistant professor of medicine at Baylor College of Medicine and the Dan L. Duncan Comprehensive Cancer Center in Houston, Texas.
This study retrospectively analyzed 62 patients with RT treated with CD19 CART across nine academic centers. The overall response rate to CD19 CART was 65%. Median progression-free survival was 4.7 months, and overall survival was 8.5 months. Increased number of prior lines of therapy was associated with worse outcomes.
This study retrospectively analyzed 62 patients with RT treated with CD19 CART across nine academic centers. The overall response rate to CD19 CART was 65%. Median progression-free survival was 4.7 months, and overall survival was 8.5 months. Increased number of prior lines of therapy was associated with worse outcomes.